Abstract Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is a multifunctional protein that was first identified in brain astrocytes and that has subsequently been shown to be expressed in different tissues. Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined. We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV). PEA-15 expression levels were immunohistochemically measured and categorized as no, low, or high expression. All tumors expressed PEA-15 in our study. Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively. In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels.
Introduction
Astrocytic tumors are the most malignant brain tumors. Despite multimodal treatment strategies that combine surgery, radiotherapy, and adjuvant chemotherapy, high-grade astrocytomas yield poor prognosis with median postoperative survival time not exceeding 12 months [1, 2] . Prognosis prediction of patients with high-grade astrocytomas is critical in selecting and evaluating the effectiveness of treatment. However, prognosis prediction based on findings by light microscopy alone is controversial, as the lack of direct knowledge about the biological behavior of highgrade astrocytomas remains an issue [1, 3] .
Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is a small protein that was first identified in astrocytes and subsequently shown to be extensively expressed in different tissues [4] . While the C-terminal of phosphoprotein contains two serine residues (Ser104 and Ser116), which can be phosphorylated by protein kinase C, calcium/calmodulindependent protein kinase II (CaMK2), and Akt, the N-terminal contains a death-effector domain (DED) [4] [5] [6] . PEA-15 has diverse functions within cells. Since PEA-15 contains a DED, it regulates apoptosis by competitively inhibiting binding of DED-containing proteins to initiator caspases [7, 8] . Apart from its apoptosis-related effects, PEA-15 is a potent modulator of mitogen-activated protein kinase (MAPK) signaling cascades. PEA-15 binds to and sequesters extracellular regulated kinase (ERK)1/2 in cytoplasm, thereby preventing its nuclear translocation [9] [10] [11] . It blocks subsequent phosphorylation of nuclear targets and ERKdependent functions such as proliferation, survival, adhesion, and migration of cells [12] . In addition, PEA-15 plays an important role in glucose metabolism, and its overexpression contributes to development of diabetes mellitus [13] .
PEA-15 is a multifunctional protein known to regulate apoptosis, proliferation, adhesion, migration, and glucose transport in cells; however, the role of PEA-15 in cancers, especially astrocytic tumors, remains unresolved. There are contradictory data with regard to the relationships between PEA-15 expression levels and tumor growth: on the one hand, increased PEA-15 levels inhibit apoptosis in nonsmall-cell lung cancer [14] , B-cell chronic lymphocytic leukemia [15] , and thyroid cancer [16] (where PEA-15 may enhance tumor growth by inhibiting apoptosis); but on the other hand, elevated PEA-15 levels inhibit ERK-dependent transcription and proliferation in ovarian [17] and breast [18] cancers. To date, the only report relating PEA-15 expression to clinical outcome has been performed in patients with ovarian cancer, and the results showed that high PEA-15 expression are independent of improved overall survival (OS) time in ovarian cancer patients [17] .
In astrocytic tumors, PEA-15 suppresses apoptosis [19, 20] by competitively inhibiting the binding of DED-containing proteins to initiator caspases same as other cancers and prevents glucose-induced cell death via the ERK pathway [21] . In astrocytes, PEA-15 prevents cell migration through a PKC delta-dependent pathway [22] . PEA-15 is known to be expressed in astrocytic tumors, but the relationship between malignancy grade in astrocytic tumors and PEA-15 expression levels is controversial [21, 23] . Moreover, the relationship between PEA-15 expression level and prognosis in astrocytic tumors remains undefined to date. In this study, we examined the expression pattern of PEA-15 in astrocytic tumors, and analyzed the relationship between PEA-15 expression level and clinical factors/outcome. Our findings confirm that PEA-15 expression is inversely associated with malignancy grade of astrocytic tumors, and this is the first study to demonstrate that decreased PEA-15 expression level is correlated with poor OS in patients with high-grade astrocytoma.
Materials and methods

Clinical data and patient selection
This study was approved by our institutional review board. Based on the World Health Organization (WHO) grading system, we conducted a retrospective study of 65 patients with newly diagnosed primary adult supratentorial diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV). These patients underwent surgical interventions at Hiroshima University Hospital, Japan, between January 1998 and March 2008. Gliomas other than those mentioned above, such as oligodendroglial tumors (including oligoastrocytoma, oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma), ependymal tumors (including ependymoma and anaplastic ependymoma), ganglioglioma, and pleomorphic xanthoastrocytoma, were excluded from the study, because these tumors are pathologically and clinically distinctly different from astrocytic tumors. We also excluded brainstem astrocytic tumors, cerebellar astrocytic tumors, gliomatosis cerebri, and recurrent tumors from the study.
We evaluated the prognostic factor in high-grade (III, IV) astrocytomas to monitor clinical outcome. Patients with diffuse astrocytoma were omitted from the prognostic study, because those with grade II tumors intrinsically indicated better prognosis than those with high-grade gliomas. Based on our institutional treatment protocol, ten patients without postoperative radiotherapy were excluded from the prognostic study. According to the protocol, patients with high-grade astrocytomas were treated with radiotherapy (extended focal 60 Gy irradiation) and administered intravenously with 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosoureal hydrochloride (ACNU) until 2006. After 2007, patients with high-grade astrocytomas were treated with radiotherapy and oral temozolomide (TMZ).
Therefore, we could retrospectively study 43 patients with anaplastic astrocytoma and glioblastoma to evaluate the prognostic factors in high-grade astrocytomas. Followup data of relevant patients were retrieved from hospital records.
Tissue specimens and immunohistochemical staining All surgically resected tumor specimens were fixed in 10% phosphate-buffered formalin before embedding in paraffin.
Representative slides were stained with the hematoxylineosin reagent for standard histological diagnosis. Tumors were histologically classified and graded into subtypes by two authors (T.S. and T.N.) according to WHO criteria. Paraffin-embedded tumor specimens were used for immunohistochemical (IHC) staining. Diluted mouse monoclonal (dilution 1:50) antibodies (antibody MIB-1; Immunotech, Marseille, France) for Ki-67 and rabbit polyclonal (dilution 1:100) antibodies for PEA-15 (antibody PEA-15; Synpep, Dubin, CA) [17] were employed as primary antibodies. Pathological specimens (thickness 4 lm) were mounted on gelatin-coated slides and deparaffinized by 15-min xylene treatment. To prevent digestion by endogenous peroxidase, the slides were immersed for 30 min in hydrogen peroxidase (3%)/methanol mixture. Each specimen was rinsed three times for a total of 15 min in phosphate-buffered saline (PBS; pH 7.5) with gentle stirring before overnight incubation with the primary antibodies at 4°C. The streptavidinbiotin procedure was next performed using the histofine SAB (R) kit (Nichirei Co., Tokyo, Japan). After washing thoroughly in PBS, the sectioned specimens were exposed to tetrahydrochloride (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in hydrogen peroxidase (0.003%)-treated PBS (pH 7.6) for 7 min. To facilitate visualization of cytoplasmic immunostaining, the slides were counterstained with Mayer hematoxylin. Each series of experiments with controls was performed at least twice on different days. We used the normal appearance of brain tissues and meningiomas as positive and negative controls, respectively.
Author F.Y., who had no knowledge of the pathologic diagnosis or any clinical or radiological data, determined the MIB-1 labeling index by counting the nuclei of 1,000 tumor cells. We selected the median value of the MIB-1 labeling index as the cutoff point, and classified the patients into two groups: i.e., Bmedian value group and [median value group.
Evaluation of PEA-15 expression
The specimens were scored by two other authors (K.S. and Y.K.), who had no knowledge of the pathological diagnosis or any clinical or radiological data. The count of positively identified tumor cells (%) was recorded for each specimen. Grading of PEA-15 expression levels was performed as follows: no or negative (no cells stained), low (up to 50% of cells stained), and high (50-100% of cells stained).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL) for Windows. Correlations between the PEA-15 expression levels and clinicopathological characteristics (including factors: age, gender, resection extent, and MIB-1 labeling index) were compared using the chi-squared test and Mann-Whitney U test. OS was derived by the Kaplan-Meier method from date of surgery. To evaluate the prognostic value, multivariate survival analysis was performed using a Cox proportionalhazards regression model, incorporating the following clinicopathological factors: age, gender, resection extent, WHO grade, MIB-1 labeling index, and PEA-15 expression level. In all analyses, differences with P \ 0.05 were considered statistically significant.
Results
Clinical characteristics and MIB-1 labeling index of grade II-IV astrocytic tumors
Of the 65 tumors, 12 were diffuse astrocytoma (grade II), 9 were anaplastic astrocytoma (grade III), and 44 were glioblastoma (grade IV). The ratio of female (n = 25) to male (n = 40) patients was 1:1. , respectively. MIB-1 labeling index showed significant differences between grade II and III (P = 0.00001) and between grades III and grade IV (P = 0.037) by Mann-Whitney U test.
PEA-15 expression and WHO grade of astrocytic tumors
We used normal intact brain tissues obtained from an epileptic patient by temporal lobectomy as the positive controls because normal astrocytes express PEA-15. We also used meningiomas for negative control because these tumors were not stained by PEA-15. In normal brain tissues, PEA-15 was stained in the cytoplasm with perinuclear and nuclear distribution. In our study, all astrocytic tumors expressed either low or high PEA-15 expression. Of these astrocytic tumors, 23 (35.4%) and 42 (64.6%) tumors expressed low (Fig. 1) and high (Figs. 2, 3, 4) PEA-15 levels, respectively, and PEA-15 was stained in the cytoplasm with perinuclear and nuclear distribution like in normal brain tissues.
We examined the relationship between PEA-15 expression and WHO grade based on the result of immunostaining studies. In diffuse astrocytoma (Fig. 2) and anaplastic astrocytoma (Fig. 3) , 100% and 88.9% of all patients expressed high PEA-15 levels, respectively. In glioblastoma, 22 (50%) and 22 patients (50%) expressed low ( Fig. 1) and high (Fig. 4) PEA-15 levels, respectively. The numbers of patients with high PEA-15 expression levels registered significant differences between grade II, III, and IV by Fisher's exact test (P = 0.0006). PEA-15 expression level was inversely correlated with WHO grade in astrocytic tumors (Fig. 5) .
PEA-15 expression and clinicopathological factors of high-grade astrocytic tumors
We evaluated the relationships between PEA-15 expression level and certain relevant clinicopathological factors in high-grade astrocytomas, such as gender, age, and MIB-1 labeling index.
PEA-15 expression correlated with neither gender (P = 0.46) when verified by chi-squared test nor age (P = 0.19) and MIB-1 labeling index (P = 0.41) when compared by Mann-Whitney U test. In fact, none of the clinicopathological factors in high-grade astrocytomas were associated with PEA-15 expression level.
Prognostic factors of high-grade astrocytoma
Next, we evaluated the prognostic factors in 43 patients with highgrade astrocytomas consisting of grade III astrocytoma (anaplastic astrocytoma) and grade IV astrocytoma (glioblastoma). Median OS of grade III astrocytomas was 1,151 (range 626-2,052) days, while that of grade-IV astrocytomas was 537 (range 93-3,548) days. The characteristics of patients (including age, gender, resection extent, MIB-1 labeling index, histopathological diagnosis, and PEA-15 expression level) are summarized in Table 1 . For 43 patients enrolled in this study, the female-to-male ratio was 1:1.9. All patients received postoperative radiotherapy based on our institutional protocol. Patients were treated with TMZ (n = 9) or ACNU-based (n = 29) chemotherapy (see ''Materials and methods'' section for details), while five cases did not receive chemotherapy. There was no difference in clinical outcome with relation to postoperative chemotherapy when verified by Kaplan-Meier method. Of 43 cases with high-grade astrocytoma, 19 (41.2%) and 24 (58.8%) tumors expressed low and high PEA-15 expression level, respectively (Table 1) . Patients with grade III astrocytomas expressed high (n = 6) and low (n = 1) PEA-15 level, while those with grade IV astrocytomas expressed high (n = 18) and low (n = 18) PEA-15 level. Fig. 1 a MRI, T2- We conducted multivariable analysis with a Cox proportional-hazards model to assess the independent predictive value of PEA-15 expression along with other prognostic factors such as age, gender, resection extent, WHO grade, and MIB-1 labeling index in patients with high-grade astrocytomas. We selected the median value of the MIB-1 labeling index as the cutoff point, and classified the patients into two groups accordingly: patients with MIB-1 labeling index of either B25% or[25%. Based on our results, patients with high-PEA-15-expressing tumors survived significantly (P = 0.0024) longer than those with low-PEA-15-expressing tumors. Kaplan-Meier OS curves with respect to the PEA-15 status also showed that the group with high PEA-15 expression had significantly (P = 0.0034, log-rank test) longer OS than that with low PEA-15 expression (Fig. 6) . In a similar tendency, patients with total resection survived significantly (P = 0.0044) longer than those without total resection, and those with MIB-1 labeling index B25% significantly (P = 0.0434) correlated with better OS. Other factors such as age, gender, and WHO grade were not correlated with prognosis (Table 2) .
Moreover, we analyzed the relationships between PEA-15 expression and OS of grade IV astrocytomas (glioblastomas). High PEA-15 expression level was statistically (P \ 0.05, log-rank test) associated with good prognosis of glioblastoma (data not shown).
Discussion
This study is novel because PEA-15 may provide a new approach for predicting prognosis of patients with highgrade astrocytomas, which has conventionally relied on WHO classification. Previous studies of astrocytic tumors have not investigated PEA-15 as a possible prognostic factor; however, the present study not only focused on the importance of PEA-15 expression as a prognosis predictor Fig. 4 [21] revealed intense PEA-15 expression in diffuse astrocytomas, anaplastic astrocytomas, and glioblastomas. In this study, we showed that PEA-15 expression is inversely associated with histological grade. Apart from the fact that PEA-15 regulates the nuclear localization of ERK1/2 and, consequently, transcription of ERK-dependent targets and cell proliferation in normal astrocytes [9] , it blocks ERK-dependent functions in astrocytic tumors as well [21] . These studies imply that the inverse association between PEA-15 expression and WHO grade may depend on the ERKdependent function. While activation of ERK1/2 is observed in cancers [12] , positive ERK1/2 immunostaining is manifested in approximately 90% of glioblastomas (i.e., displaying mainly nuclear immunolocalization) [24] . Furthermore, phosphorylated-ERK (p-ERK)-positive tumor nuclei are significantly associated with lower OS [24] . These results suggest that nuclear translocation of p-ERK may be increased by degradation of PEA-15 expression, and sequentially results in poor prognosis. Therefore, PEA-15 could functionally be considered as an anti-oncogene. In fact, another study on PEA-15 and astrocyte migration [22] also indicated that PEA-15 functions as an anti-oncogene in astrocytes. In that study, loss of PEA-15 expression resulted in increased astrocyte migration, probably via a PKC delta-dependent mechanism [22] . Clinical studies of PEA-15 and malignant conditions support the fact that PEA-15 functionally serves as an antioncogene. In breast [18] and ovarian [17] cancers, PEA-15 binds to and sequesters ERK1/2 in cytoplasm, thereby inhibiting ERK-dependent transcription and proliferation. Moreover, PEA-15 expression is inversely correlated with the invasive behavior of tumor cells by preventing ERK signaling of integrins in breast cancer [18] . In a previous immunohistochemical study investigating the effect of PEA-15 expression on OS in 395 women with primary ovarian cancer, patients with high PEA-15 expression survived significantly (P \ 0.05) longer than those with low PEA-15 expression [17] . These results coincide well with our present results. Furthermore, their results show that presence of PEA-15 expression in ovarian cancer cells inhibits tumor cell proliferation and induces autophagy as well as upregulation of PEA-15 expression to prevent nuclear translocation of ERK1/2 and subsequent ERKstimulated transcription and proliferation.
PEA-15 not only prevents proliferation, adhesion, and migration of cells, but this multifunctional protein also regulates apoptosis and glucose transport. Increased PEA-15 levels inhibit apoptosis in B-cell chronic lymphocytic leukemia [15] and thyroid cancer [16] . In these tumors, PEA-15 inhibits Fas, tumor necrosis factor-a (TNF-a), and TNF-related apoptosis-inducing ligand (TRAIL)-activated apoptosis by localizing the death-inducing signaling complex (DISC) via binding to the Fas-associated death domain protein (FADD), thereby preventing recruitment of death-initiating caspase-8. These in vitro studies suggest that PEA-15 may enhance tumor growth by preventing apoptosis in some cancer cell lines. In a mouse model for chemically induced skin carcinogenesis, PEA-15 has also been shown to promote skin tumors and is overexpressed in transformed and metastatic murine squamous carcinoma cells, suggesting that PEA-15 probably displays both antiapoptotic and tumorigenic functions [25] . However, findings on the association of PEA-15 expression with either malignancy grade of cancers or poor prognosis have yet to be documented in a clinical setting. PEA-15 expression in non-small-cell lung cancers has previously been implied in a clinical setting [14] . However, detailed analysis of tumor-node-metastasis (TNM) staging revealed that PEA-15 expression is more intensive during early (T1 and N0) than subsequent (T2 and N1 lesions) stages of the disease [14] , implying that PEA-15 was not functioning as an oncogene, probably because of decreased PEA-15 expression in high-grade tumors. Certain differences in PEA-15 expression in malignant tumors could be due to the phosphorylation status of PEA-15, which may be important in determining whether PEA-15 regulates cell proliferation or apoptosis [10] . PEA-15 is phosphorylated at position Ser104 by protein kinase C and at Ser116 by CaMK2 and Akt, thus producing three isoforms: nonphosphorylated, monophosphorylated, and diphosphorylated forms of the PEA-15 protein. Nonphosphorylated PEA-15 tends to block cellular proliferation by inhibiting nuclear translocation of p-ERK1/2, whereas phosphorylated PEA-15 has lost the ability to bind ERK1/2, followed by initiation of antiapoptotic and prosurvival transcriptional signaling [4] [5] [6] . Furthermore, Renganathan et al. [26] have demonstrated that phosphorylation at Ser104 triggers inhibition of ERK binding to PEA-15 and facilitates ERK translocation to the nucleus, while phosphorylation at Ser116 promotes PEA-15 binding to FADD to subsequently inhibit apoptosis. Further studies on phosphorylation of PEA-15 are warranted to clarify the role of PEA-15 in cancers.
Overall, this study has the following limitations and implications for future strategies: (1) the sample comprised only 43 patients with high-grade astrocytic tumors, therefore warranting further confirmatory investigations with larger patient populations; (2) postoperative chemotherapy was varied, so the relation between PEA-15 expression and outcomes with a common treatment modality for brain tumor needs to be explored; (3) the phosphorylation status of PEA-15 in the enrolled high-grade astrocytoma patients was unknown (PEA-15 expression may depend on phosphorylation status), thus the mechanism will be better clarified with an identified phosphorylation status; (4) only PEA-15 expression level and MIB-1 labeling index were examined, and other relevant molecules (such as p16, p53, ERK, epidermal growth factor receptor, etc.) which may serve as important prognostic factors in astrocytic tumors should be measured; (5) ERK localization was not examined (although we have reviewed these molecules sequentially), and future investigations should incorporate this cellular event; (6) PEA-15 could functionally be considered as an anti-oncogene (although the function of PEA-15 is not fully resolved), and therefore examining short interfering RNA (siRNA) of PEA-15 with respect to phosphorylation site may help monitor malignant transformation in malignant gliomas; and (7) this study was based on a retrospective design, and therefore prospective study is essential to confirm our present findings.
In conclusion, we have demonstrated that PEA-15 expression level is inversely correlated with WHO grading of astrocytic tumors. Low PEA-15 expression is associated with poor prognosis in patients with high-grade astrocytoma. Our findings may provide a foundation for predicting clinical outcomes in patients with high-grade astrocytoma, and encourage possible incorporation of new therapeutic options in the treatment strategy.
